Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer.
Wen-Ting PengXi JinXiao-En XuYun-Song YangDing MaZhi-Ming ShaoYi-Zhou JiangPublished in: Cancer research (2023)
ACAA1 is highly expressed in TNBC, serving as a potential therapeutic target in ACAA1-high tumors and a predictive biomarker of resistance to CDK4/6 inhibitors for RB1-proficient patients.